Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence
Immunetune has developed unique proprietary technologies enabling next-generation best-in-class DNA vaccines against cancer and infectious diseases.
DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide and RNA vaccines and cell therapies.
Finalizing preclinical package to initiate clinical studies in 2023
Preclinical Proof of Concept in cancer models including combination with checkpoint inhibitors
Seeking funding by life science investors and partnerships in oncology & infectious diseases
Immunetune is based in Leiden, the Netherlands, and is committed to develop best-in-class vaccines and bring them to patients with a sense of purpose and urgency.
News & Events
Nature Communications publication on SARS-CoV-2 vaccine development by Immunetune
Immunetune's development of a vaccine against SARS-CoV-2 has been published as part of a consortium in Nature Communications in July 2022. In this specific publication, named 'A third vaccination with a single T cell epitope confers protection in a murine model of...
ACIR features Immunetune’s presentation at CIMT Annual Meeting 2022
Accelerating Cancer Immunotherapy Research (ACIR) has featured Immunetune's presentation during the Cancer Immunotherapy (CIMT) Annual Meeting 2022 held May 10-12 in Mainz, Germany. At CIMT, our CSO Jeroen van Bergen presented new preclinical results on our neoantigen...
Immunetune and Daicel Initiate Research Collaboration on Vaccine Injection Device
Immunetune and Daicel Initiate Research Collaboration on Vaccine Injection Device LEIDEN, the Netherlands; OSAKA, Japan; April 22, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases,...